ORIC-944
Phase 1Small molecule
ORIC-944 is one of 49 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Metastatic Prostate Cancer
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Casodex
IIstituto Clinico Humanitas
Approved
Revia
TevaApproved
Zytiga
Johnson & JohnsonPhase 3
Xtandi
AstellasPhase 3
Firmagon
FerringApproved
Taxotere
AAvyxa
Phase 3
Erleada
Johnson & JohnsonPhase 3
Nubeqa
BayerPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ORIC-944. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- OORIC Pharmaceuticals